Plexiform Neurofibroma
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 program1
TQ-B3234 capsulesPhase 31 trial
Active Trials
SpringWorks TherapeuticsCT - Stamford
1 program1
MirdametinibPhase 2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Chia Tai TianQing Pharmaceutical GroupTQ-B3234 capsules
SpringWorks TherapeuticsMirdametinib
Clinical Trials (2)
Total enrollment: 114 patients across 2 trials
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Start: Feb 2026Est. completion: Dec 2028
Phase 3Not Yet Recruiting
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Start: Sep 2019Est. completion: Dec 2028114 patients
Phase 2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space